Join top execs online + in NYC — May 15
No images? Click here
Presented by
In collaboration with
Biopharma 2025: US-China, AI, and what’s next
US-China relations have become a definitive double-edged sword for biopharma. Licensing innovative drugs from China may provide a boost for businesses, but legislation to restrict work with Chinese companies could erect barriers.
As decision-makers navigate a disruptive life sciences landscape, Endpoints News Executive Editor Drew Armstrong will moderate a high-stakes conversation — live in New York City and online next week — on the political risks and commercial opportunities reshaping the industry.
Join us to explore:
- The changing shape of the US biopharma workforce
- Finding pharma's next great blockbuster
- Solving pharma’s R&D conundrum: Making AI work
- What does Trump 2.0 mean for biopharma?
Hosted by FT Live in partnership with Endpoints News, this event brings together top executives, investors, and science leaders to unpack the future of biopharma in the US and beyond.
Who you could meet next week — in person
This keystone gathering attracts C-suite leaders from global biopharma, forward-looking investors, and scientists shaping the next wave of medicine. Want to see who’s attending? Enter your details to explore the full list of companies.
Featured Speakers
Calley Means, Co-Founder, TrueMed and Senior Advisor to Secretary Robert F. Kennedy Jr., Department of Health & Human Services
Christopher Boerner, Board Chair and CEO, Bristol Myers Squibb
Stephan Jenn, President, Novalix
Faisal M. Khan, Corporate VP, AI and Analytics, Novo Nordisk
Hesham Abdullah, Senior Vice President, Global Head of Oncology, Research and Development, GSK
Priya Singhal, Executive VP and Head of Development, Biogen
View the full agenda here.
In collaboration with
Global Drug Discovery Partner
Strategic Partner
Lead Sponsor
Networking Sponsor
Associate Sponsors
